Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Lipodystrophy is a group of acquired and inherited disorders characterized by selective loss of adipose tissue. Despite wide genotypic and phenotypic variety, many patients with lipodystrophy have similar metabolic complications including insulin resistance, diabetes mellitus, hypertriglyceridemia and hepatic steatosis. Often, these metabolic abnormalities are severe and difficult to treat with conventional glucose and lipid-lowering therapies. Lack of adipose tissue also results in marked hypoleptinemia, and there has recently been much interest in using leptin-replacement therapy to treat the metabolic complications of lipodystrophy. Administration of metreleptin, the human recombinant leptin analogue, has been shown in prospective, open-label studies to improve glucose control, dyslipidemia and steatohepatitis. This article summarizes the current evidence for the safety and efficacy of leptin-replacement therapy in patients with lipodystrophy.

Original languageEnglish (US)
Pages (from-to)205-212
Number of pages8
JournalExpert Review of Endocrinology and Metabolism
Volume9
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Lipodystrophy
Leptin
Adipose Tissue
Glucose
Hypertriglyceridemia
Fatty Liver
Dyslipidemias
Insulin Resistance
Diabetes Mellitus
Therapeutics
Lipids
Safety
metreleptin
Liver

Keywords

  • Diabetes mellitus
  • Hypertriglyceridemia
  • Insulin resistance
  • Leptin therapy
  • Lipodystrophy
  • Metreleptin
  • Steatohepatitis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy. / Simha, Vinaya.

In: Expert Review of Endocrinology and Metabolism, Vol. 9, No. 3, 01.01.2014, p. 205-212.

Research output: Contribution to journalArticle

@article{2618bc81357445eca348b8c291100d09,
title = "Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy",
abstract = "Lipodystrophy is a group of acquired and inherited disorders characterized by selective loss of adipose tissue. Despite wide genotypic and phenotypic variety, many patients with lipodystrophy have similar metabolic complications including insulin resistance, diabetes mellitus, hypertriglyceridemia and hepatic steatosis. Often, these metabolic abnormalities are severe and difficult to treat with conventional glucose and lipid-lowering therapies. Lack of adipose tissue also results in marked hypoleptinemia, and there has recently been much interest in using leptin-replacement therapy to treat the metabolic complications of lipodystrophy. Administration of metreleptin, the human recombinant leptin analogue, has been shown in prospective, open-label studies to improve glucose control, dyslipidemia and steatohepatitis. This article summarizes the current evidence for the safety and efficacy of leptin-replacement therapy in patients with lipodystrophy.",
keywords = "Diabetes mellitus, Hypertriglyceridemia, Insulin resistance, Leptin therapy, Lipodystrophy, Metreleptin, Steatohepatitis",
author = "Vinaya Simha",
year = "2014",
month = "1",
day = "1",
doi = "10.1586/17446651.2014.894877",
language = "English (US)",
volume = "9",
pages = "205--212",
journal = "Expert Review of Endocrinology and Metabolism",
issn = "1744-6651",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy

AU - Simha, Vinaya

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Lipodystrophy is a group of acquired and inherited disorders characterized by selective loss of adipose tissue. Despite wide genotypic and phenotypic variety, many patients with lipodystrophy have similar metabolic complications including insulin resistance, diabetes mellitus, hypertriglyceridemia and hepatic steatosis. Often, these metabolic abnormalities are severe and difficult to treat with conventional glucose and lipid-lowering therapies. Lack of adipose tissue also results in marked hypoleptinemia, and there has recently been much interest in using leptin-replacement therapy to treat the metabolic complications of lipodystrophy. Administration of metreleptin, the human recombinant leptin analogue, has been shown in prospective, open-label studies to improve glucose control, dyslipidemia and steatohepatitis. This article summarizes the current evidence for the safety and efficacy of leptin-replacement therapy in patients with lipodystrophy.

AB - Lipodystrophy is a group of acquired and inherited disorders characterized by selective loss of adipose tissue. Despite wide genotypic and phenotypic variety, many patients with lipodystrophy have similar metabolic complications including insulin resistance, diabetes mellitus, hypertriglyceridemia and hepatic steatosis. Often, these metabolic abnormalities are severe and difficult to treat with conventional glucose and lipid-lowering therapies. Lack of adipose tissue also results in marked hypoleptinemia, and there has recently been much interest in using leptin-replacement therapy to treat the metabolic complications of lipodystrophy. Administration of metreleptin, the human recombinant leptin analogue, has been shown in prospective, open-label studies to improve glucose control, dyslipidemia and steatohepatitis. This article summarizes the current evidence for the safety and efficacy of leptin-replacement therapy in patients with lipodystrophy.

KW - Diabetes mellitus

KW - Hypertriglyceridemia

KW - Insulin resistance

KW - Leptin therapy

KW - Lipodystrophy

KW - Metreleptin

KW - Steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=84899067628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899067628&partnerID=8YFLogxK

U2 - 10.1586/17446651.2014.894877

DO - 10.1586/17446651.2014.894877

M3 - Article

AN - SCOPUS:84899067628

VL - 9

SP - 205

EP - 212

JO - Expert Review of Endocrinology and Metabolism

JF - Expert Review of Endocrinology and Metabolism

SN - 1744-6651

IS - 3

ER -